TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $5.79 billion. The enterprise value is $5.73 billion.
Important Dates
The last earnings date was Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 145.23 million shares outstanding. The number of shares has increased by 7.96% in one year.
| Current Share Class | 145.23M |
| Shares Outstanding | 145.23M |
| Shares Change (YoY) | +7.96% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 7.32% |
| Owned by Institutions (%) | 72.17% |
| Float | 134.54M |
Valuation Ratios
The trailing PE ratio is 265.73 and the forward PE ratio is 37.51. TG Therapeutics's PEG ratio is 0.33.
| PE Ratio | 265.73 |
| Forward PE | 37.51 |
| PS Ratio | 17.61 |
| Forward PS | 9.66 |
| PB Ratio | 25.81 |
| P/TBV Ratio | 26.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.33 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 245.14 |
| EV / Sales | 17.42 |
| EV / EBITDA | 136.49 |
| EV / EBIT | 136.71 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.
| Current Ratio | 6.25 |
| Quick Ratio | 4.85 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 5.74 |
| Debt / FCF | n/a |
| Interest Coverage | 1.75 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 7.00%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 5.78% |
| Return on Invested Capital (ROIC) | 7.00% |
| Return on Capital Employed (ROCE) | 8.61% |
| Revenue Per Employee | $973,385 |
| Profits Per Employee | $69,180 |
| Employee Count | 338 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.51 |
Taxes
In the past 12 months, TG Therapeutics has paid $2.21 million in taxes.
| Income Tax | 2.21M |
| Effective Tax Rate | 8.64% |
Stock Price Statistics
The stock price has increased by +156.01% in the last 52 weeks. The beta is 2.30, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 2.30 |
| 52-Week Price Change | +156.01% |
| 50-Day Moving Average | 34.34 |
| 200-Day Moving Average | 27.20 |
| Relative Strength Index (RSI) | 57.27 |
| Average Volume (20 Days) | 3,583,575 |
Short Selling Information
The latest short interest is 25.74 million, so 17.73% of the outstanding shares have been sold short.
| Short Interest | 25.74M |
| Short Previous Month | 26.88M |
| Short % of Shares Out | 17.73% |
| Short % of Float | 19.14% |
| Short Ratio (days to cover) | 7.84 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $329.00 million and earned $23.38 million in profits. Earnings per share was $0.15.
| Revenue | 329.00M |
| Gross Profit | 290.52M |
| Operating Income | 41.93M |
| Pretax Income | n/a |
| Net Income | 23.38M |
| EBITDA | 42.00M |
| EBIT | 41.93M |
| Earnings Per Share (EPS) | $0.15 |
Full Income StatementBalance Sheet
The company has $311.00 million in cash and $254.38 million in debt, giving a net cash position of $56.62 million or $0.39 per share.
| Cash & Cash Equivalents | 311.00M |
| Total Debt | 254.38M |
| Net Cash | 56.62M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 222.36M |
| Book Value Per Share | 1.54 |
| Working Capital | 475.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$40.52 million and capital expenditures -$45,000, giving a free cash flow of -$40.56 million.
| Operating Cash Flow | -40.52M |
| Capital Expenditures | -45,000 |
| Free Cash Flow | -40.56M |
| FCF Per Share | -$0.28 |
Full Cash Flow StatementMargins
Gross margin is 88.30%, with operating and profit margins of 12.74% and 7.11%.
| Gross Margin | 88.30% |
| Operating Margin | 12.74% |
| Pretax Margin | 7.78% |
| Profit Margin | 7.11% |
| EBITDA Margin | 12.76% |
| EBIT Margin | 12.74% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.96% |
| Shareholder Yield | -7.96% |
| Earnings Yield | 0.40% |
| FCF Yield | -0.70% |
Dividend DetailsAnalyst Forecast
The average price target for TG Therapeutics is $40.67, which is 2.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $40.67 |
| Price Target Difference | 2.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 37.02% |
| EPS Growth Forecast (5Y) | 100.29% |
Stock ForecastsStock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 0.0177777:1.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.0177777:1 |
Scores
TG Therapeutics has an Altman Z-Score of 3.11 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.11 |
| Piotroski F-Score | 3 |